4th Quarter - Report
THE D MAJOR GROUP for ALLERGAN INC (FORMERLY ACTAVIS INC )
Firm
Income
$45,000
Expenses
—
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Issues concerning patent reform, including H.R. 9 The Innovation Act, and S. 1137, the Protecting American Talent and Entrepreneurship Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE MAJOR | Health Policy Analyst for Senate Republican Policy Committee |
| BRENDA REESE | Conference Coordinator for House Republican Conference |
Health Issues HCR
Issues related to pharmaceutical drug approval processes and scientific review best practice standards. Monitor H.R. 34, The 21st Century Cures Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE MAJOR | Health Analyst for the Senate Republican Policy Committee |
| BRENDA REESE | Conference Coordinator for the House Republican Conference |
Budget/Appropriations BUD
Issues related to FDA product surveillance funding, including H.R. 2028, Further Continuing & Security Assistance Appropriations Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE MAJOR | Health Policy Analyst for Senate Republican Policy Committee |
| BRENDA REESE | Conference Coordinator for House Republican Conference |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.